CureVac, a leading clinical stage biotechnology company in the field of messenger RNA and one of Germany’s leading contenders to develop a COVID-19 vaccine, said it aims to raise up to $245 million in an initial public offering (IPO) on the US Nasdaq, according to Reuters. The biotech firm said it plans to offer a…